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DURING THE PAST 30 YEARS ORTHOTOPIC LIVER TRANSPLANTATION HAS BECOME A highly successful form of surgical treatment.'-3 The significant advances 
achieved in this field have led to an increased demand for organs and created a 
wide gap between organ availability and organ supply.4 
A wider availability of organs for transplantation would allow an expansionS rather 
than a contraction of the indications for transplantation, and, at the same time a relax-
ation of the patient selection criteria.6,7 All these facts clearly justify the renewed 
interest observed in the last decade in xenotransplantation.8 
The original concept of xenografting, meaning the transplantation of cells, tissues, 
or organs between different species, is so ancient that it is easily recognizable in Greek 
and Roman mythology. The centaur Chiron,9 the teacher of Esculapius, and the 
Chimera'o are legendary examples of discordant" xenogeneic creatures_ 
However, it is oruy during this century that scientists have been able to bring this idea 
intO the clinical arena. The early efforts were prompted by the shortage of humans organs 
at a time when there were few alternatives for treating end-stage organ failure. I H4 
The first three attempts at whole organ 
xenotransplamanon were made in France 
and Germany between fanuary and April 
1906 usmg a pig. a goat, and a rna~que as 
kidney donors. ll.13 None of these kidneys 
tunctloned because ot almost Immewate 
vascular thromboSIS, and the human reclpi-
c:ntS died in less than 3 days. In a further 
;mempt In 1923 by keuhotl~ :l lamb was 
used as a kidney donor and the patlent wed 
atter <) days. Un February 16, 1963, 
Hitchcock of the Henneptn County 
Hospital to Minneapolis, transplanted the 
kidney ot a baboon to a 6S-year-old woman. 
The organ tuncuoned ior 4 dayS before ItS 
. Hterv clotted. ls A few months bter on 
October H, 1 Y63, Reemtsma 01 Tulane 
UniversitY used a Rhesus monkey as a kid-
nev donor tor a human reCIpient who sur-
vived 12 days. Then, Rcemtsma tried agam 
with a senes of 6 consecutive chimpanzee 
kidney gratts.11> One of these xenografts 
tunctloned for 270 days. 
In December [963 and Tanuary 1964, 
SIX patients were transplanted uSing 
baboon kidneys at the University ot 
Colorado In Denver.18 All of these kid-
neys worked Immewately and sustamed 
,I dlalysls-iree liie tor 10 to 60 days. 
The patients were on heavy doses 01 aza-
t hlOpnne and prednisone and in 4 of 
them St!PSIS was the leading cause ut 
Jeath, whIle relectlOn was maInly 
responsible tor the other two deaths . 
However, the relectlOn pathology was not 
qualitlyely dlifcrent trom that observed 
10 allograrts.': s In [984, slmdar 
Immunopatholol/:lCal t!vents caused tat!-
AIded bv oe~arch Grants from the Veterans Ailirurusu~uon and Prolect Gram No. DK 29961 tram the 
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ure of a baboon heart transplanted in a 
2,200 gr neonate, known as Baby Fae,14 
after 20 days, Despite heavy cyclosporine-
sterOId immunosuppresslOn. 
A pig kidney and a pig heart trans-
planted respectlvelv by KusS26 and Ross2-1 
in the '60s were hyperacutely rejected in 
d matter of minutes, clearly demonstrat-
ing that the pig was not and will not be 
dn easy donor tor a human recipient. 
THE ANTIPROLIPE.R.ATIVE DRUGS 1 
Sir Peter Medawar, in 1969, stated that: 
"A new solution IS therefore called for: 
the use at heterografts - that is to say, of 
grafts transplanted from lower animals 
into man. Of the use of heterografts I can 
say only thiS: that In the laboratory we 
dre achievmg greater success with grafts 
between species today than we achieved 
With gratts Wltrun l5 years ago. We shall 
sohl: the problem by usmg heterografts 
one dav 1t we try hard enough, and maybe 
in less than l5 years". 27 However, the 
laboratory work performed at different 
institutions in the following 15-20 years 
did not bring particularly encouragmg 
results in further clinical trials. In May 
1992 the results of a study performed in 
Pittsburgh by Dr. Noriko M~ase et al,28 
were discussed at the meeting of the 
American Society of Transplant Surgeons 
in Chicago. Murase's work clearly 
showed, in a hamster-to-rat xenotrans-
plant model, that when FKS06 treatment 
was combined with either of two 
"antiproliferatlve" drugs that" suppress 
purine iRS 614431 or pyrimidine 
(Brequmarl ribonucleotide synthesis for 
the first two post-transplant weeks, 
indefinite survival under continued 
FKS06 alone was routinely achievable, 
The use of cyclophosphamide, an alkylat-
ing agent with conSiderable B cell specI-
ficity,29,30 allowed simHar consistent 
chrornc survival after either heart or liver 
xcnotransplantauon. Parncularly signili.-
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cant was the fact that a single large dose 
of cyclophosphamide, given 10 days 
before the xenotransplant, allowed suc-
cess ill almost 100% of the animals with 
daily admlnIstratIon of FKS06 only. 
When cyclophosphamide had been used 
in the past for kidney and intestinal 
transplants in the dog, there was no pro-
longation of graft survival, or else the 
effect was a minor one.J1 .33 The dog may 
have been an mappropriate model to 
evaluate cyclophosphamide for human 
immunosuppression.J1.33 How-ever, the 
successful use of this drug by Santos et 
a1.34,35 in bone marrow grafts, and by 
other authors in a few cases of clinical 
kidney transplantation,J6,37 prompted its 
use at the UniversIty of Colorado in a 
series of liver and kidney transplant 
patients, as the baseline for chronic ther-
apy, in combination With prednisone and 
horse antilymphocyte globulin,J8,39 
Later, a more extensive report was pub-
lished agam by the Denver group.oW This 
previous clinical use of cyclophos-
phamide as an effectlve drug 10 trans-
plant patients appeared to lustify its use 
in clinical xenograft trials,28 
Clinical Trial 
On rune 28, 1992, and on fanuary 10, 
1993, two patients aged 35 and 62 years 
respectively, suffering from end stage 
liver disease related to hepatitis B virus 
(HBVI underwent a liver xenotransplanta-
tion (Table 1). The chosen donor was the 
baboon Papio cynocephalus. Theoretical· 
ly, at least.3 arumal-human combinatIons 
Figurw 2. Bf~n liver XlltlClll'llllplentldlon 
Case 2. ChoIqiognm performed on pcIIt-opennmt 
day 18.1IIIougII1IIe indwelling bilia/Y c:adIeI8r pieced 
and exwiorized IllIIIe time at IIIe 1UIlJIIY. The arrow 
showslh. choledocftoj.junOSlOllly on • ",WI .... \' 
bo_lloop. Th. bili.ry clllhlllltr pl.cld in Case 2 
.IIOWIId f1IIIIine coIlec8oa DIllie bil. during 1M poli-
o .... coune.. (Nom: Marino IR. Tzakia AG. fung 
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possibly qualified for this xenouansplan-
tatlOn attempt. The Rhesus monkey-to-
human. the baboon-to-human. and the 
chimpanzee-to-human. The Rhesus mon-
key had been used in 1963 by Reemtsma 
for an heterotopIc lollipop kidney trans-
plant. The Rhesus kidneys were aggres-
sively relected in a few days. 16 The use of 
the baboon at the University of Colorado 
allowed a dialysIs free survival of the ure-
mic patient for up to 60 days, and only 
two of the 6 patients transplanted died 
from reiection. The chimpanzee was used 
at Tulane University agam by Dr. 
Reemtsma and one of his patients lived 
for mne months WIthout dialvsls, and 
succumbing only to an acute illness of 
undetermined etIOlogy (probably pneu-
montal. Consequentlv, on the baSIS of the 
preVIOUS experience the chimpanzee 
could seem the best possible donor. 
I fowever, It IS an endangered species and 
111 the LJ .5. onl y hetween 25 and 50 chim-
panzees per ve:u would be avadable for 
,til biomedical research, Including that In 
the Important frelds of hepatitis and 
AIDS' I :\Iso, It has been calculated that 
only 70 chimpanzees could be available 
world wide as organ donors. 42 The use of 
chimpanzees would further Jeopardize 
this species without solving the organ 
shortage problem. 
The baboon. thus, appeared to be the 
only possible donor choice, and the liver 
seemed to be the organ to use in the clin-
ical trial, because its relative resistance 
to humoral rejectlOn. 4"49 
The pharmacological cocktail used for 
the prevention and the control of relec-
tion was made by "old" immunosuppres-
sants (sterOids, cyclophosphamide and 
Prostoglandin E 1),1,2.29·35.38.40.44 . .10 and 
"new" immunosuppressants (FKS061.51 
Donor Surveillance and Selection 
The baboons for the donor selection were 
provided by the Southwest Foundation 
for Research and Education (SFREI, San 
:\monio, Texas, who also proVided the 
haboons for the prevIOus Denver senes of 
haboon-to-human renal xenotransplanta-
tlonKl~ All of the baboons involved m the 
donor selectIOn process were PaplO cyno-
(cphalus, and were born In the U.S.A. at 
General Surgery 
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SFRE.S2 Baboons have weakly expressed 
A, B, and AB blood types on all celis, and 
wtll rarely have type a blood group/53 but 
ABO incompatibility did not influence 
the outcome in previous human 
xenograft trials (1,18). Thus, ABO match 
m baboon-to-human xenotransplantation 
IS desirable but not mandatory. However, 
both of our patients had ABO compatible 
donors: A to A in Case 1, and B to B in 
Case 21Table 11. 
The conventIOnal lymphocytotoxic 
cross match of the recipient sera to their 
Jonor lymphocytes was positive in both 
cases but negative after dithiothreltol 
treatment. During the selection process 
the baboons underwent a complete bio-
chemical and infectious disease work-up. 
This work-up was performed at the Virus 
Reference Laboratory of SFRE and includ-
e d screening for retroviruses I STLV, 
HTLV, SIV, SRV1, SRV2, SRVS, HIV1, 
HIV2, and foamy virus I, Herpes viruses 
,SA8, HSV, BVirus, rCMV, hCMV, EBV, 
Jnd VZVI, and hepatitiS viruses IHBV, 
HAV, Jnd HCV), Marburg Virus, 
cncephalomyocarditis virus, lympho-
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Figure 3. Clinical course atter baboon-to-human liver transplant Casa 1. SM. 
SolumedrolJE {methylprednisolona,; PGE_ prostaglandin E,; Bx. liver biopsy; 
AST. aspanate aminotnlnsferese: ALT. alanine eminotransfenlse; Alk Ph, alka-
line phosphatase.lfrom: Starz! TE. fung J. Tzakis A. Todo S. Demetris AJ. 
Manno IR. Doyle H. Zeevi A. Wany V, Michaels M. Kusne S. Ruden WA. Trucco 
M: Baboon to human liver tnlnsplantallon. lancet 341(88311:6571. 1993. Used by 
08nn1SSlon./ 
Figure 4. Clinical course atter baboon-Io-human liver transplant Case 2. SM, 
SolumedrolJE (methylprednisolone); PGE. prostaglandin E,; Bx. liver biopsy: 
AST. aspanate amlRotransferese: ALT, alanine aminotransferase: WBC. while 
blood cell count. tfrom: Stanl TE. Tzakis A. Fung JJ, Todo S, Marino IR. 
Demelns AJ: Human liver xenotnlnsplantallon. Xeno. 1ft press. Used by peml1s-
sion.' 
Liver XenotrllnspidDtDtion 142 MARINO, TZAKIS, rUNG, TODO, DOYLE, MANEZ, STARZL 
chorIomeningitis ViruS, and hemorrhagic 
fever virus. The animals were also 
screened for tuberculosis and toxoplas-
mosIs and blood and stool cultures were 
obtained. 
Both Paplo cvnocephalus donors were 
healthy and found to be antibody poSitive 
for foamy ViruS, EBV, CMV, and Simian 
agent 8. In addition the donor to the first 
patient had VZV antlbodies. The 
donor/reclplent weights were 25.8170 Kg 
In Case 1 and 35.8/80.4 Kg in Case OK~4Ipp 
Donor and Recipient Operations 
The donor operation for the liver harvest-
ing from the two baboons was performed 
according to our donor standard tech-
nique SA The donor and recipient opera-
tions were performed in two different 
tlperatlng rooms, With the donor opera-
tions starting sltghtiy after the reCipient 
llperatlOns to minimiZe the cold ische'mta 
time II J 7 minutes In Case l. Jnd 231 
I11lnutes In Case 21. The haboon donor 
livers were prescrved with the Universltv 
ot WisconSin solution. 
Both bahoon-to-human liver xeno-
transplantatiOnS were performed uSing a 
piggyback technlque,.i7 ~lnd a venovenous 
bypass,.ix ~f mOllification of the standard 
techmque for orthotopIC liver transplan-
tation described .10 years agoK·i~ 
SpeCifically due to the small size ot the 
donor livers 1(,(JOg ami 4S0g, respective Iv 
In C.lse j .1Ilt! l~Klse 21, and the Size dis-
crepancy hetween the reCipient and the 
donor ycssds. the reCipient'S nght hepat· 
IL veins werc cltlsed With a runnIng 
,uturc, .llld the d'll1lH upper cava was 
,IIJastomosni cnd·(O·c:nd to an adequate 
dltt tJShllll1cd uSing the reCIpients l111d-
dk and ktt i1ep'lllc veins. The donor cdl' 
.IL .IXIS was .1l1.1stoll1osed end·w·end to 
the reClpl!.:nt Cl)llllllOn hepatic artery 111 
l=JSC j .• 1I1d el1l!·((1·'lJe on the supra cdl-
ac reCipient aorta in Case 2, by interposi-
tion of a donor carotid graft. The donor 
portal vein was anastomosed on the 
stump of the reCipient left portal vein in 
Case I, while the size match allowed a 
direct porta-to-porta anastomosis in Case 
2. The liver reperfused promptly and um-
formly (Figure II in both cases. The post-
reperluslOn biopsies showed a good liver 
architecture, With a moderate degree of 
sinusoidal neutrophilic aggregates. The 
biliary reconstruction, with a Roux-en- Y 
choledochoielunostomy in both cases. 
However, in Case 2 an indwelling biliary 
catheter was placed at the time of the 
operation and extenonzed. This catheter 
i Figure 2) allowed routine collection of 
the bile during the post-operative course 
of the second patient. 
Postoperative Course 
The ImmunosuppressIOn was based on 
the use ot 4 drugs: cyclophosphamide, 
FKS06, methylprednisolone and PGE I. 
Doses and routes of administration are 
reported in Figure J and 4. Cyclophos-
phamide was started 2 days before the 
xenotransplants, and was given for 56/70 
days In Case I and 10126 days in Case 2, 
.It a dose ranging from 0.07 to 10.6 
mg/kg/day. FKS06 was started the same 
day of the xenografts and, except for high· 
er doses given during the nrst '2 postoper-
.1tlVe weeks 111 Case l, the doses were 
Within standard therapeutic r:Inges. 
Detailed descnptlOns of the immunosup-
pressive drug doses and of their blood lev-
els have been recently reported else-
\\! hereK·i~KDi:;Dw 
Some ot the dcmographlc charactens-
(ICS ot the .2 patients are shown In Table l. 
l\oth patients had end-stage chroniC 
.H:tlVe hepatitis caused by hepatitis II 
virus IHBVI. The eYldcnce that the 
haboon liver would be resistant to the 
HBVS4 that reinfects most al!ografts 
under comparable circumstance61 pro-
moted the selection of these two candi-
dates who had already been refused 
human liver transplantation at other 
Institutions. Some dIfferences between 
the two patients could have impacted on 
the efficacy of perioperative immune 
modulation. The second patient was 
nearly twice as old and far more frail than 
the first patient. Also, the second patient 
did not have a splenectomy, and the 
spleen was removed on day postoperative 
4. The first patient underwent splenecto-
my in 1989 after a motorcycle accident. 
Both patients were immunocompetent at 
the time of the xenograft, although the 
first also had an HIV infectionY Both 
patients were in stage 3 coma during the 
24 hours preceding the surgery. The first 
patient woke promptly, was extubated 
Jfter 17 hours, and was eating and walk-
in~ within S days. He had an almost nor-
mal bilirubm for the malonty of the 70 
days of sumval (Figure 31. He also spent 
almost 30 days 10 a regular ward. The 
second patlent, by contrast, remained 
lctenc IFigure 4), and comatose and was 
mechanically ventilated for the 26 days 
of survival. Both patients suffered from 
hypoalbuminemia and received frequent 
albumin mfusion. s4,ss The first patient 
went into renal failure on postoperative 
dav 21, whIle the second patient became 
~fnuric immedi:ltely after sur~eryK 
PaplO cynoccph:llus normally produce 
elevated kvels of factor VII and low Iev-
t.:ls of factors IX and XI, as compared t 
humans. C0agulatlon pranles were dOlh 
In both rl:Clplents preoperatively and sev· 
eral tllnes postoperatlvelv. Our results, 
reported elsewhere,',2 demonstrated that 
(he baboon's coagulation pattern was 
.lcqulfed by the patient after liver 
xenografung. This fact, however, did not 
Figure 5. Baboon-Io-human liver uanspllRt Case t. CT scan of Ihl abdomen 
periormed on posloperauV8 dlY 24. Thl CT-calcuilled liver volume was 
1,555ce. The willie Insert shows Ihe onginll volume of Ihe baboon liver on Ihe 
"au fti .h. t"In~njKnf1SllcclK 
Figure 6. Baboon-to-humin liver transpllnt Case 2. CT scan of Ihe abdomen 
performed on posloper.llve dlY 14. The CT-celeulated livlr volume wll 
1.741cc. The while inse" shows Ihl onginal volume of Ihl baboon liver on lite 
day of lIIe transplant 145Occl. 
aitect the clottmg ability of the patients. 
Dunng their postoperative courses the 
patients underwent several liver biopsies 
\6 in patient 1 and 8 in patient 2. includ-
mg the autopsv specimens\. Only the 
bIOpsy obtamed from the first patIent on 
the 12th postoperative day had signs of 
mild focal cellular relection. while no 
eVIdence of cellular reiection was detect-
t:d In anv ot the other biopSies from 
eIther patlent:D~:iRKSKP No evidence of HEV 
remtectlon was detectable bv 
immunoperoxidase staining in the liver 
tissue at anv time In the two patients. 
!loth baboon li vers underwent a dra-
matlcal regeneration after the xenograft. 
with tnpling or quadrupling the organ 
volume withIn the first month. Figure 5 
and 6 show the change In size ot the liv-
as alter the xenografts. calculated by CT 
,can. with the standard method routmely 
used in our liver panents.64 
The rour drug ImmunosuppressIve 
cocktaIl IFK506. methylprednisolone. 
PGE I. and cvclophosphamidel prevented 
these twO liver xenografts from being 
destroved bv cellular as well as humoral 
releCtion. The role played by cyclophos-
phamIde and other" antiproliferattve" 
drugs m the Murase's cxperiments lB 
reported above. was largely conrl.rmed by 
thIS clinical tnal. 
The «Iuse of death was diffuse sub-
arachnOId hemorrhage and left uncal brain 
stem hermatlon. secondary to an)?)OInva-
,lye aspergillosis ill Case 1, artd sepsIs trom 
penronltls III Case 2. DetaIls at the necrop-
-Ies have been reponed elsewhere.5-+,·" 
IMMUNOLOGIC AND 
METABOLIC QUESTIONS 
The liver. 111 the hamster-to-rat 
xcnogrJIt model, demonstrated a umque 
.lbtlltv til resIst n':lectlon more than 
'1ther EFrgans~pI .md was also found to be 
,lll1e [0 ~dllcld other concomltantlv 
transrlan[ed organs trom relectIon."·' 
\Is(), IIH: liver can resIst the attack 01 
:'retormed xeno;lnubodles.'" The devat-
c·d l111101l11t ot dendritic cells and other 
""lie thSUe icukocvtes ;lllie to leave 
. c tL111splJnted organ and tnduce svs-
'lIC llllcrochllTIenSm makcs the ltver 
'l1unOllH.!ICldlv rrtvdcgcd. The rro-
,iLtI011 (}[ thIS ceil chlmensm IS. tn tJct. 
. :le hJ'IS "I lIr"Jn trJnsplant accq1tance 
lild tll!crancc ,r, Cr.:ll chImerIsm was 
;'rOVl'1l III (ile Tlrst r;ltlent. where 
h.lbolln ll:"-J t\ was (Ound 111 manv organs 
.it necropsv, lllciud111g the heart. lung, 
kidney .111\1 j vmrh l1odes. AugmentatlOn 
,1 thIS ceil g111~r:ltlln WilS Jrrempted tn 
: l1e ,n:llllll patient iw mtuslUn 01 the 
,jlJnor h,lhOO!l none marrow ceils ;lIter 
::1C rL'f'ertUSIO!l or rhe lIver .. ,\li the 
blood samples collected for this purpose 
during his postoperative course demon-
strated clearly evidence ot cell 
crumensm by PCR. 
A baboon It ver transplanted in a 
human being contmues to synthesize pro-
tein with the donor phenotype_ This con-
cept IS the basis for liver allotransplanta-
tion in many human congenital metabolic 
diseases. 67,68 Thus. a baboon-to-human 
liver xenograft creates in the recipient a 
baboon-specIfic hepatic metabolism. This 
fact was already demonstrated in the ham-
ster-to-rat combinatlon. two rodents 
philogenetically far diiferent for 15-40 mil-
lion years.69 The study of clotung factors 
in these two arumals showed sigruficant 
differences. and when a rat received a 
hamster liver its coagulation profile 
became identical to the donor pattern. 70 
However, the recipIent rat does not suffer 
from any coagulative diathesis. 
Similar changes happened in the 
human xenogratts with changes in the 
metabolIsm of hepatic based clotting fac-
tors, albumm, several globulins, uric 
'!CId, and cholesterop4.S5 The sUlVlval of 
the two patients was too short to accu-
rately state whether or not these events 
could be the source of a long term meta-
bolic baboon/human incompatibility_ 
The other open question IS related to 
the complement role in these clinical 
xenotransplants. It has been shown that 
total complement was significantly 
depleted in the first 10 postoperative days 
while C3, C.+ and C5 were undetectable 
In the first 1.+ gavs:F~IRR }\lso, dunng the 
tirst postoperative H davs CirculatIng anti-
,.;en-antlbodv complexes were present. 
.-Vter this lUlUal phase the total comple-
ment returned to almost a normal con-
centration. The Important role ot com-
pkment JctlvatlOn with neutrophIl par-
tICipation was emphaSIzed 25 vears ago 
hv revealing the analogy 01 hvperacute 
kIdnev relection with the Shwartzman 
,md Arthur reactions. ~fK 72 
Expenments ,limed to block the path-
l'.L:emCltv de[!ved bv the cleavage or C3 
;mc..l CS are bemg currentlv conducted In 
the laboratorIes Ilt the Pittsburgh 
fr:msplantauon institute. 
CONCLUSION 
: t IS OhVIOllS that a prolect ot thIS nature 
r.l1ses problt:ms that kave the medll:al 
,irea and dtrectlv mvolve ethIcal Issues. 
l'ew ethIcal movements belteve that such 
,i prolect IS unethIcal. -.l We do not thmk 
that thIS IS the n01t place 1m opemng a 
,kbate hetween advocates lit mterspeCles 
L''-!ualHv, J moJern ialrusm .. ~ beilevers 01 
InterspeCles lI1equailtv. lInd speClelsrs. '; 
However. we appreciate and share the 
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feelings of Stephen Post 73 who stated 
that the Pittsburgh prolect "has success-
fully reminded us that the human good 
remains appropnately the highest good, 
despite the cultural inroads of anthropo-
morphism_" • STI 
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